Clinical stage biopharmaceutical company CureVac has commenced a Phase IIb clinical trial of mRNA-based cancer vaccine CV9104 in patients with castration-resistant prostate cancer.

The double-blind, randomised trial will enrol a total of 200 patients across Europe to evaluate CV9104 in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer patients who are new to chemotherapy.

University of Tubingen, Germany, urology department medical director and the study coordinating investigator Dr Arnulf Stenzl said; "This trial will validate the safety and investigate the clinical efficacy of CureVac’s first-in-class mRNA-based cancer vaccine technology, RNActive, in patients with metastatic castration refractory prostate cancer."

Overall survival is the primary endpoint of the study CV9104.

CureVac chief executive officer Ingmar Hoerr said the RNActive vaccines have been shown to be safe, and induce balanced humoral and cellular immune responses against multiple cancer antigens.

"Because of the robust immune response induced by our mRNA vaccine, we expect CV9104 to yield significant clinical benefit for patients with advanced prostate cancer," Hoerr said.

"We believe that RNActive vaccines have the potential to provide a safe and effective treatment option for patients with prostate cancer and other malignancies."

Image: Micrograph of prostatic adenocarcinoma, conventional (acinar) type, the most common form of prostate cancer. Photo: Courtesy of Nephron.